Double-Drug strike aims to halt MS early
NCT ID NCT07517185
First seen Apr 09, 2026 · Last updated May 09, 2026 · Updated 2 times
Summary
This study tests whether giving two strong medications one after the other can safely control relapsing-remitting multiple sclerosis (MS) in its early stages. Sixty adults aged 18-50 with active MS will receive rituximab infusions followed by cladribine tablets, then be monitored for 2 years. The main goal is to check for serious side effects, while also tracking brain lesions, relapses, and disability progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING REMITTING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centralsjukhuset Karlstad, Neurologi och Rehabiliteringskliniken
Karlstad, 651 85, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Falu Lasarett, Neurologen
Falun, 79182, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Gävle sjukhus, Neurologmottagningen
Gävle, 80324, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Uppsala University Hospital
Uppsala, 75185, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.